Last updated on August 2019

Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG


Brief description of study

The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.

Clinical Study Identifier: NCT02684058

Find a site near you

Start Over

Novartis Investigative Site

Parkville, Australia
1.87miles
  Connect »